PRICES include / exclude VAT
Homepage>ASTM Standards>07>07.100>07.100.01>ASTM E3042-16R24 - Standard Practice for Process Step to Inactivate Rodent Retrovirus with Triton X-100 Treatment<rangeref></rangeref >
Sponsored link
Released: 01.02.2024

ASTM E3042-16R24 - Standard Practice for Process Step to Inactivate Rodent Retrovirus with Triton X-100 Treatment<rangeref></rangeref >

Standard Practice for Process Step to Inactivate Rodent Retrovirus with Triton X-100 Treatment<rangeref></rangeref >

Format
Availability
Price and currency
English PDF
Immediate download
58.86 USD
English Hardcopy
In stock
58.86 USD
Standard number:E3042-16R24
Released:01.02.2024
Status:Active
Pages:4
Section:14.01
Keywords:biological pharmaceutical drug substance; biopharmaceutical manufacturing; detergent inactivation; enveloped virus; IgG Fc fusion protein; log10 reduction value; modular viral clearance; monoclonal antibody; recombinant protein; retrovirus; Triton X-100; viral clearance; viral inactivation;
DESCRIPTION

1.1 This practice assures effective inactivation of 4 log10 of infectious rodent retrovirus (that is, reduction from 10 000 to 1 infectious rodent retrovirus or removal of 99.99 % of infectious rodent retroviruses) in the manufacturing processes of monoclonal antibodies or immunoglobulin G (IgG) Fc fusion proteins manufactured in rodent-derived cell lines that do not target retroviral antigens. Rodent retrovirus is used as a model for rodent cell substrate endogenous retrovirus-like particles potentially present in the production stream of these proteins.

1.2 The parameters specified for this practice are clarification, Triton X-100 detergent concentration, hold time, pH, and inactivation temperature.

1.3 This practice can be used in conjunction with other clearance or inactivation unit operations that are orthogonal to this inactivation mechanism to achieve sufficient total process clearance or inactivation of rodent retrovirus.

1.4 This detergent inactivation step is performed on a clarified, cell-free intermediate of the monoclonal antibody or IgG Fc fusion protein.

1.5 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.6 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.

1.7 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.